Pennant Group’s Q1 2026 Earnings Snapshot

Pennant Group (PNTG) opened 2026 with Q1 revenue of US$285.4 million and basic EPS of US$0.25, while trailing twelve month revenue stood at US$1.0 billion with EPS at US$0.88. This provides a clear baseline for the latest earnings season read through. Over the last year, the company has seen revenue move from US$695.2 million to US$1.0 billion on a trailing basis, with EPS lifting from US$0.72 to US$0.88 and net income from US$22.6 million to US$30.3 million. The current figures therefore sit against a backdrop of earnings growth, modest profit margins and a stock price of US$35.73, which keeps the focus on how durable those margins appear.

See our full analysis for Pennant Group.

With the core numbers on the table, the next step is to see how this earnings profile lines up with the key narratives around Pennant Group, and where the data either supports those stories or raises questions about them.

TTM earnings up 19.2% with 3% margin

• On a trailing basis, net income over the last 12 months is US$30.3 million on US$1.0b in revenue, which works out to a 3% net profit margin compared with 3.4% a year ago and 19.2% earnings growth over that same period.
• Supporters of a bullish view often point to this 19.2% earnings growth and the 35.8% annual earnings compounding over five years as evidence of a solid earnings engine. However, the slip in margin from 3.4% to 3% keeps the focus on how much of that growth comes from higher volumes versus improved profitability.
  • The trailing 12 month revenue line moved from US$695.2 million to US$1.0b while net income rose from US$22.6 million to US$30.3 million, so profit scaled with sales but not enough to lift the margin.
  • For a bullish thesis built around earnings growth, that mix of higher earnings and slightly thinner margins suggests future performance may hinge on whether margins can at least hold around the current 3% level.

Many investors now ask whether that earnings growth story is already fully reflected in the stock or if there is still room for the bullish case to play out further in the numbers. 📊 Read the what the Community is saying about Pennant Group.

Premium 41.2x P/E against healthcare peers

• The stock trades on a trailing P/E of 41.2x versus a peer average of 25.7x and a broader US Healthcare industry average of 22.4x, which means you are paying a higher price per dollar of trailing earnings than for many comparable healthcare stocks.
• Bears often argue that this kind of premium multiple is hard to justify, and the current setup gives them some support because the 3% net margin is modest and slightly below last year, even while the P/E sits well above sector and peer levels.
  • With the share price at US$35.73 and trailing EPS of US$0.88, the high P/E lines up with the valuation data and highlights how much weight the market is putting on the earnings story relative to current profitability.
  • Critics also point to the company’s high level of debt in the risk summary, which, combined with a rich P/E and thin margin, adds an extra consideration for investors who are sensitive to balance sheet risk when paying up for growth.

DCF fair value at US$72.08 vs US$35.73 price

• The provided DCF fair value estimate of US$72.08 per share sits about 50.4% above the current share price of US$35.73, even though trailing net profit margin is only 3% and earnings over the last year grew 19.2%.
• Supportive investors often highlight that earnings are forecast to grow around 28.1% per year and to outpace the broader US market, and the DCF fair value estimate backs that growth focused view. However, the same data set also shows revenue growth expectations of 9.3% per year and a slight margin compression, which means the optimistic case leans heavily on sustained earnings expansion from a relatively low margin base.
  • The gap between the 28.1% earnings growth forecast and the 9.3% revenue growth forecast suggests expectations for further shifts in profitability or mix, even though the recent move from a 3.4% to 3% margin points in the opposite direction.
  • That tension between a high implied upside to DCF fair value and a modest profit margin may lead some investors to compare the DCF view with the premium 41.2x trailing P/E, and decide how much growth they are comfortable underwriting at today’s price.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Pennant Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Seeing both risks and potential rewards in the numbers so far, it makes sense to look through the data and stress test your own thesis quickly. To balance the upside story against the concerns highlighted by other investors, take a closer look at the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Pennant Group combines a modest 3% net margin and high 41.2x P/E with balance sheet concerns, which can make that earnings focused story feel fragile.

If you are uneasy about paying up for thin margins and flagged debt risks, it makes sense to compare this setup with solid balance sheet and fundamentals stocks screener (44 results) right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.